Efficacy of telithromycin in community-acquired pneumonia caused by Legionella pneumophila

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 23, Issue 8, 2004, Pages 650-652

  Carbon, C ^a,b   Nusrat, R ^a  

^a SANOFI   (France)

^b NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LEVOFLOXACIN; TELITHROMYCIN; TROVAFLOXACIN;

ARTICLE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; HYPOTENSION; LEGIONELLA PNEUMOPHILA; PRIORITY JOURNAL;

ADOLESCENT; ADULT; COMMUNITY-ACQUIRED INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL COOPERATION; KETOLIDES; LEGIONELLA PNEUMOPHILA; LEGIONNAIRES' DISEASE; MACROLIDES; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 4544227836     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-004-1152-2     Document Type: Article

References (17)

1. Joseph C (2002) New outbreak of Legionnaires' disease in the United Kingdom. Br Med J 325:347-348
2. Barman Balfour JA, Figgitt DP (2001) Telithromycin. Drugs 61:815-829
3. Vazifeh D, Preira A, Bryskier A, Labro MT (1998) Interactions between HMR 3647, a new ketolide, and human polymorphonuclear neutrophils. Antimicrob Agents Chemother 42:1944-1951
4. Khair OA, Andrews JM, Honeybourne D, Jevons G, Vacheron F, Wise R (2001) Lung concentrations of telithromycin after oral dosing. J Antimicrob Chemother 47:837-840
5. Hammerschlag MR, Roblin PM, Bébéar CM (2001) Activity of telithromycin, a new ketolide antibacterial, against atypical and intracellular respiratory tract pathogens. J Antimicrob Chemother 48:25-31
6. Edelstein PH, Edelstein MAC (1999). In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia. Antimicrob Agents Chemother 43:90-92
7. Hagberg L, Carbon C, van Rensburg DJ, Fogarty C, Dunbar L, Pullman J (2003) Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis. Respir Med 97:625-633
8. Hagberg L, Torres A, van Rensburg D, Leroy B, Rangaraju M, Ruuth E (2002) Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia. Infection 30:378-386
9. Dunbar LM, Hassman J, Tellier G (2004) Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. Clin Ther 26:48-62
10. Tellier G, Isakov T, Peterman W, Patel MP, Lavin B (2002) Efficacy and safety of telithromycin (800 mg once daily) for 5 or 7 days vs clarithromycin (500 mg twice daily) for 10 days in the treatment of patients with community-acquired pneumonia. In: Program and abstracts of the 42nd Interscience Conference on antimicrobial agents and chemotherapy. Abstract no. L-373
11. Pullman J, Champlin J, Vrooman PS (2003) Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults. Int J Clin Pract 57:377-384
12. Carbon C, Moola S, Velancsics I, Leroy B, Rangaraju M, Decosta P (2003) Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia. Clin Microbiol Infect 9:691-703
13. Fogarty C, Patel TC, Galbraith H, Zuberbuhler GA, Leroy B (2001) Efficacy of the first ketolide antibacterial, telithromycin, in the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae. In: Program and abstracts of the 41st Interscience Conference on antimicrobial agents and chemotherapy. Abstract no. L-857
14. van Rensburg DJ, Matthews PA, Leroy B (2002) Efficacy and safety of telithromycin in community-acquired pneumonia. Curr Opin Med Res 18:397-400
15. Fogarty C, van Rensburg D, De Salvo C, Rangaraju M, Nusrat R (2004) Efficacy of a 7-day course of oral telithromycin 800 mg once daily in community-acquired pneumonia caused by resistant Streptococcus pneumoniae. In: Abstracts of the 14th European Congress of clinical microbiology and infectious diseases. Abstract no. P451
16. Gleason PP (2002) The emerging role of atypical pathogens in community-acquired pneumonia. Pharmacotherapy 22(Suppl 1 Pt 2):2-11
17. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336:243-250